Clinical trials: Conduction Defect
Ventricular Tachycardia
Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia
Ventricular tachycardia (VT) is a morbid arrhythmia responsible for many sudden deaths and ICD shocks. Despite much progress in the treatment of arrhythmia, VT remains a therapeutic challenge.
- Trial name
- NCT00721032
- Testing
- MRI guided VT ablation, Increased dose of amiodarone
- Where
- United States
- Sponsor
- Johns Hopkins University
Sick Sinus Syndrome, Paroxysmal Atrial Fibrillation
Optimal Sensing in Atrial Tachyarrhythmia's Study
The aim of the study is the comparison of two different leads in their capabilities to detect episodes and duration of paroxysmal atrial fibrillation (AF) and atrial tachyarrhythmia (AT), and the rejection of far field sensing of…
- Trial name
- OSAT (NCT01074749)
- Testing
- Accent Pacemaker
- Where
- Netherlands
- Volunteers
- 111 people
- Sponsor
- Abbott Medical Devices
Myocardial Infarction, Coronary Artery Disease
Arrhythmias in Post-Myocardial Infarction Patients
Patients are screened for significant arrhythmias and other possibly significant ECG-patterns directly after discharge and two weeks after myocardial infarction using wearable devices.
- Conditions
- Myocardial Infarction, Coronary Artery Disease, Arrythmia, ECG Electrical Alternans
- Trial name
- NCT03231826
- Where
- Finland
- Volunteers
- 445 people
- Sponsor
- Tampere University
Ventricular Premature Complexes, Blood Pressure
Premature Ventricular Contractions (PVCs) and Blood Pressure Control
The purpose of this study is to determine if reduction in premature ventricular contraction (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma catecholamines and an improvement in baroreflex gain.
- Trial name
- NCT01833455
- Testing
- PVC Suppression using Flecainide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Wisconsin, Madison
Recurrent Ventricular Tachycardia
Intramural Needle Ablation for Ventricular Tachycardia
This is a single-arm non-randomized prospective observational cohort study to assess the outcomes of patients undergoing intramural needle catheter ablation of recurrent ventricular tachycardia that has failed antiarrhythmic drug…
- Trial name
- NCT02799693
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- John Sapp
Atrial Flutter, Ventricular Tachycardia
Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies
The purpose of this clinical study is to collect safety and performance data to support a demonstration of substantial equivalence of the Catheter Robotics Remote Catheter System to predicate devices when used to perform EP…
- Trial name
- NCT01139814
- Testing
- Amigo catheter robot
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 181 people
- Sponsor
- Catheter Robotics, Inc.
Long QT Syndrome Type 3
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3.
- Trial name
- NCT02300558
- Testing
- Eleclazine
- Where
- 12 sites in United States, Canada and 6 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Tachycardia; Paroxysmal, Supraventricular, Tachycardia, Supraventricular
Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias
The aim of this single-center prospective randomized controlled trial is to assess the superiority of contact-force-(CF)-sensing-based approach compared to conventional (non-CF-sensing) approach in the catheter ablation of PSVTs…
- Trial name
- COBRA-PATH (NCT04078685)
- Testing
- Standard catheter ablation, Contact Force-sensing-based catheter ablation
- Where
- Netherlands
- Volunteers
- 113 people
- Sponsor
- Erasmus Medical Center
Solid Tumors
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under…
- Trial name
- NCT03258515
- Testing
- AZD6094 200 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrioventricular Block, Progressive Cardiac Conduction Defect
Cohort Description of Younger With AV-block
Background: Disturbances of the heart's atrioventricular conduction - AV-block - may show by shortness of breath, fainting or sudden death. If AV-block is diagnosed in time pacemaker therapy may be lifesaving.
- Conditions
- Atrioventricular Block, Progressive Cardiac Conduction Defect, Genetic Disease
- Trial name
- NCT03024047
- Testing
- Pacemaker
- Where
- Denmark
- Volunteers
- 1,255 people
- Sponsor
- University of Aarhus
Heart Failure, Left Bundle-Branch Block
Optimised MultiSite Pacing Vector Study
The objective of this clinical investigation is to evaluate the clinical benefits of an MultiSite pacing (MSP) with patient specific left ventricular vector optimization in patients receiving cardiac resynchronization therapy…
- Conditions
- Heart Failure, Left Bundle-Branch Block, Systolic Dysfunction
- Trial name
- NCT03938090
- Testing
- Optimised MultiSite Pacing, Standard biventricular pacing
- Where
- United Kingdom
- Sponsor
- Barts & The London NHS Trust
Atrioventricular Reentrant Tachycardias, Wolff-Parkinson-White (WPW) Syndrome
Comparative Outcomes of Radiofrequency Ablation of Concealed and Manifest Accessory Pathways: a Single Center, Retrospective Observational Study
The aim of this observational, retrospective study is to evaluate, comparatively, procedural outcomes of APs (Accessory pathway) ablation according to the conduction properties (i.e., manifest vs.
- Trial name
- NCT07435181
- Volunteers
- 220 people
- Sponsor
- IRCCS Ospedale San Raffaele
Brugada Syndrome
DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome
The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD) is implanted to prevent sudden cardiac death.
- Trial name
- DAPREB (NCT00701077)
- Testing
- 3,4-Di-amino-Pyridine
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sudden Cardiac Death, Heart Failure
Cardiac Rehab Retrospective Review (CR3)
All patients enrolled in the Austrian LifeVest Registry will be retrospectively screened for successfully completed ambulatory or stationary rehabilitation program.
- Conditions
- Sudden Cardiac Death, Heart Failure, Ventricular Arrythmia, Ventricular Tachycardia
- Trial name
- CR3 (NCT04675957)
- Testing
- cardiac rehabilitation
- Where
- Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies
Mayo AVC Registry and Biobank
Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT03049254
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Sick Sinus Syndrome
Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)
The purpose of this study is to determine the incidence of atrial fibrillation and heart failure in patients with pacemaker therapy with different pacing modes (AAI, DDD, and a novel algorithm to minimize ventricular pacing).
- Trial name
- NCT00161551
- Testing
- Vitatron T70 DR
- Where
- 5 sites in Germany
- Volunteers
- 402 people
- Sponsor
- Medtronic BRC
Tachyarrhythmias, Sudden Cardiac Death
SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients
The purpose of this study is to characterize the chronic performance of the St. Jude Medical SJ4 connector and RV high voltage SJ4 leads.
- Conditions
- Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT00940888
- Testing
- SJ4 connector and RV high voltage SJ4 lead
- Where
- United States
- Volunteers
- 1,701 people
- Sponsor
- Abbott Medical Devices
Long QT Syndrome
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of eleclazine and its metabolite, GS-623134, in participants with normal and impaired renal function.
- Trial name
- NCT02441829
- Testing
- Eleclazine
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Ventricular Tachycardia
Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation
This study aims to assess whether a combined technique of substrate ablation and ablation of the clinically presenting VT at the site of early activation is superior to ablation of the clinically presenting VT alone, in enhancing…
- Trial name
- VISTA (NCT01045668)
- Testing
- Radiofrequency Catheter Ablation (RFCA)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Ventricular Tachycardia, Monomorphic, Cardiomyopathies
Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia
Ventricular tachycardia (VT) is a dangerous fast heart rhythm originating from scarred areas of the heart muscle, often after a heart attack or in patients with cardiomyopathy.
- Trial name
- START-VT (NCT07618780)
- Testing
- Stereotactic Arrhythmia Radioablation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Southlake Health